Loading…
Employees: 295
Size Jin Medical International (ZJYL) is a United States Health Care company (Medical Specialties) with a market value of $532M, the 2647th largest of 3,117 United States companies the cockpit tracks. Shares closed at $3.36 on 6 Nov 2026.
Performance Over six months the shares gained 52.7%, against -14.2% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue fell 13.6% over the last twelve months (peer median +6.9%); the operating margin is 2.1% (peer median -1.9%).
Valuation It trades at 26.5× enterprise value to sales against a peer median of 3.9× (2nd most expensive of 17).
Capital Return on invested capital runs 17.7 points below its cost of capital (19.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $19.7M | $20.7M | $23.5M | $19.8M | $19.2M |
| Revenue growth | — | -12% | +19% | +3% | — |
| Gross profit | $6.04M | $6.04M | $9.50M | $6.78M | $6.20M |
| EBITDA | $704,460 | $932,860 | $3.97M | $3.09M | $2.49M |
| Net income | $1.17M | $1.19M | $3.68M | $2.88M | $2.71M |
| Free cash flow | -$6.96M | -$3.73M | -$1.35M | $2.99M | $1.54M |
| Capital expenditure | $6.37M | $6.63M | $1.12M | $113,937 | $40,166 |
| Total debt | n/a | $18.5M | $11.4M | $4.11M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZJYL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +58.5% | -4.3% | highest of 20 |
| 6-month return | +52.7% | -14.2% | 2nd highest of 20 |
| Distance from 52-week high | -60.4% | -37.3% | 2nd lowest of 20 |
| Revenue growth (TTM) | -13.6% | +6.9% | 2nd lowest of 20 |
| Operating margin | 2.1% | -1.9% | 10th highest of 20 |
| EV / Sales | 26.5× | 3.9× | 2nd most expensive of 17 |
| ROIC minus cost of capital | -17.7 pp | -6.5 pp | 3rd lowest of 17 |
| Net debt / EBITDA | -13.5× | -2.1× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| medmix MEDX.SW | Switzerland | $537M | +24% | -7% | 6% | 1.5× | 5.0% | +5.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $537M | -32% | +9% | 3% | 2.3× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $538M | -25% | -21% | -7% | n/a | n/a | n/a |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $542M | -3% | +23% | 31% | 8.0× | 6.3% | +24.4% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Nanjing Vishee Medical Technology 688580.SS | China | $550M | -40% | +7% | 24% | 6.0× | 22.3% | +4.2% |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | 7.3× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $555M | -14% | -10% | -4,738% | 134.2× | n/a | n/a |
| Sight Sciences SGHT | United States | $555M | -14% | +9% | -33% | 6.2× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $556M | -4% | +14% | 2% | 1.7× | 7.4% | -7.8% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $559M | -17% | +18% | -60% | 2.0× | n/a | n/a |
| Anbio Biotechnology NNNN | United States | $560M | -85% | +10% | 67% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $566M | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $566M | +38% | -3% | -11% | 0.8× | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $568M | -5% | -7% | 4% | 4.5× | 2.7% | -13.2% |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |